University of Cambridge > > Cambridge Oncology Seminar Series > "Exploiting ASS1 deficiency in the treatment of mesothelioma"

"Exploiting ASS1 deficiency in the treatment of mesothelioma"

Add to your list(s) Download to your calendar using vCal

If you have a question about this talk, please contact Mala Jayasundera.

Malignant pleural mesothelioma is an intractable asbestos-related cancer with a median survival of less than 12 months and an estimated total economic burden running into several billion pounds. We have identified epigenetic loss of the rate-limiting enzyme for arginine synthesis argininosuccinate synthetase (ASS1) in mesothelioma cells revealing a novel Achilles’ heel using arginine deprivation. A CRUK -funded randomized phase 2 trial of the arginine-depleting agent ADI -PEG20 and best supportive care (Polaris Group, US) versus best supportive care alone is underway in patients with ASS1 -deficient mesothelioma in the UK. Current preclinical and clinical work will be discussed with an emphasis on developing arginine deprivation as a novel therapeutic option for patients with mesothelioma and other ASS1 -deficient cancers.

This talk is part of the Cambridge Oncology Seminar Series series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.


© 2006-2023, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity